Drug Profile
Palivizumab biosimilar - mAbxience
Alternative Names: MB-05Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator mAbxience
- Developer mAbxience; University Medical Center Utrecht
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in Netherlands (IM, Injection)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in Spain (IM, Injection)
- 31 Mar 2023 mAbxience completes a phase I FANTASY-A trial in Respiratory syncytial virus infections (Prevention) in Australia and New Zealand (IM) (NCT05121246)